Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.61 |
| ▸ | MAOB known ✓ | P27338 | 5/20 | 0.48 |
| ▸ | MAOA known ✓ | P21397 | 3/20 | 0.48 |
| ▸ | HTR2A known ✓ | P28223 | 1/20 | 0.42 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | AGXT | P21549 | 1/20 | 0.44 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL583541 | 0.97 | TAAR1 (0.64) | TAAR1SLC6A2SMN1; SMN2HIF1AMAOB | |
| Iodide SCHEMBL5092148 | 0.94 | TAAR1 (0.61) | TAAR1SLC6A2SMN1; SMN2HIF1AMAOB | |
| Bromide SCHEMBL5087806 | 0.94 | TAAR1 (0.61) | TAAR1SLC6A2SMN1; SMN2HIF1AMAOB | |
| Water SCHEMBL8366271 | 0.94 | TAAR1 (0.61) | TAAR1SLC6A2SMN1; SMN2HIF1AMAOB | |
| Hydrochloric Acid SCHEMBL11047140 | 0.87 | TAAR1 (0.54) | TAAR1SLC6A2SMN1; SMN2HIF1AMAOB | |
| Hydrochloric Acid SCHEMBL7033437 | 0.85 | SLC6A2 (0.58) | TAAR1SLC6A2SMN1; SMN2HIF1AMAOB | |
| Hydrochloric Acid SCHEMBL3889042 | 0.85 | KDM4E (0.55) | TAAR1SLC6A2SMN1; SMN2HIF1AMAOB | |
| Hydrochloric Acid SCHEMBL27811779 | 0.85 | SLC6A2 (0.52) | TAAR1SLC6A2SMN1; SMN2HIF1AMAOB | |
| SCHEMBL29342 | 0.84 | TAAR1 (0.56) | TAAR1SLC6A2SMN1; SMN2HIF1AMAOB | |
| Hydrochloric Acid SCHEMBL4650598 | 0.84 | TAAR1 (0.50) | TAAR1SLC6A2SMN1; SMN2HIF1AMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114231115-A | Graphene single-component aqueous epoxy resin emulsion and preparation method thereof | 杭州烯创科技有限公司 | 2022-03-25 | — | — | CN | claimed |
| US-20250092071-A1 | PROCESS FOR PREPARING ISOCYANATOORGANOSILANES | WACKER CHEMIE AG (DE) | 2025-03-20 | — | — | US | disclosed |
| EP-4472991-A1 | PROCESS FOR PREPARING ISOCYANATOORGANOSILANES | Wacker Chemie AG (DE) | 2024-12-11 | — | — | EP | disclosed |
| WO-2023143749-A1 | PROCESS FOR PREPARING ISOCYANATOORGANOSILANES | WACKER CHEMIE AG (DE) | 2023-08-03 | — | — | WO | disclosed |
| CN-114231115-A | Graphene single-component aqueous epoxy resin emulsion and preparation method thereof | 杭州烯创科技有限公司 | 2022-03-25 | — | — | CN | disclosed |
| US-20080214386-A1 | Stability; easily separated from solution; surface treatment of catalyst with Group seven compound; reacting epoxide with carbon dioxide | NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY (JP) | 2008-09-04 | — | — | US | disclosed |
| US-20050009967-A1 | Phosphite stabilizers and methods to preparation and polymer composition thereof | CROMPTON CORPORATION | 2005-01-13 | — | — | US | disclosed |
| WO-2004111158-A1 | PHOSPHITE STABILIZERS AND METHODS TO PREPARATION AND POLYMER COMPOSITION THEREOF | CHEMTURA CORPORATION (US) | 2004-12-23 | — | — | WO | disclosed |
| US-5322659-A | Anticlotting the medical tubes by complexing the quaternary ammonium salt in the lamination layer with a reagent solution consisting of an anticoagulants heparin, an antiinfection agents | BECTON, DICKINSON AND COMPANY (US) | 1994-06-21 | — | — | US | disclosed |
| US-5235086-A | From 2,4-di-tert-butylphenol and phosphorus trichloride in the presence of catalysts | CIBA-GEIGY CORPORATION (US) | 1993-08-10 | — | — | US | disclosed |
| US-4739090-A | REACTING PHOSPHOROUS TRICHLORIDE, PENTAERYTHRITOL, AND ALKYL PHENOL IN PRESENCE OF CATALYST | ADEKA ARGUS CHEMICAL CO., LTD. (JP) | 1988-04-19 | — | — | US | disclosed |
| US-4492661-A | Process for producing triarylphosphites | CIBA-GEIGY CORPORATION (US) | 1985-01-08 | — | — | US | disclosed |
| US-4440696-A | FROM A PHENOL AND PHOSPHORUS TRIHALIDE, AMINE OR AMIDE CATALYST | CIBA-GEIGY CORPORATION (US) | 1984-04-03 | — | — | US | disclosed |
| US-4312818-A | CATALYZED REACTION OF A PHENOL WITH A PHOSPHORUS HALIDE | CIBA-GEIGY CORPORATION (US) | 1982-01-26 | — | — | US | disclosed |
| US-4251469-A | ADDITIVES FOR EXTREME PRESSURE LUBRICANTS | CIBA-GEIGY CORPORATION (US) | 1981-02-17 | — | — | US | disclosed |
| US-4197209-A | Lubricant compositions containing sulfur-containing esters of phosphoric acid | CIBA-GEIGY CORPORATION (US) | 1980-04-08 | — | — | US | disclosed |
| US-4189453-A | FROM MERCAPTANS AND PHOSPHORUS TRIHALIDE, CATALYTIC | CIBA-GEIGY CORPORATION (US) | 1980-02-19 | — | — | US | disclosed |
| US-3992370-A | 1,1-Dichloro-1a,1b-dihydrodibenzo(b,f)cycloprop(d)azepine-6(1H)-carboxaldehyde | TAKEDA CHEMICAL INDUSTRIES, LTD. (JA) | 1976-11-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250092071-A1 | PROCESS FOR PREPARING ISOCYANATOORGANOSILANES | ADH1C, SCLY, MPST | SLC6A2 2463/4885MAOB 2227/4885MAOA 2708/4885 |
| US-20050009967-A1 | Phosphite stabilizers and methods to preparation and polymer composition thereof | PHOSPHO1, OR51E2, CDIPT | SLC6A2 3673/4885MAOB 3508/4885MAOA 3332/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.